Who is sponsoring NCT03963414?

NCT03963414 is sponsored by University of Nebraska.

What drugs are being tested in NCT03963414?

Interventions in NCT03963414: Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide.

What condition does NCT03963414 study?

NCT03963414 studies Small Cell Lung Carcinoma.

Is NCT03963414 still recruiting?

NCT03963414 is currently terminated. Last updated 28 August 2023.

Last reviewed 2023-08-28 · How we verify

NCT03963414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Terminated Phase 1 Last updated 28 August 2023

What this trial tests

Phase 1 trial testing Durvalumab + Tremelimumab in combination with carboplatin and etoposide in Small Cell Lung Carcinoma in 1 participant. Terminated before completion.

Timeline

25 September 2020

Primary endpoint
15 December 2021

15 December 2021

Quick facts

Lead sponsor	University of Nebraska
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	25 September 2020
Primary completion	15 December 2021
Estimated completion	15 December 2021
Sites	1 location across United States

Drugs / interventions tested

Durvalumab + Tremelimumab in combination with carboplatin and etoposide
Durvalumab in combination with carboplatin and etoposide

Conditions studied

Small Cell Lung Carcinoma — all drugs for Small Cell Lung Carcinoma →

Sponsor

University of Nebraska

Who can join

18 and older, any sex, with Small Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Combination therapy: Future directions of immunotherapy in small cell lung cancer.
Huang W, Chen JJ, Xing R, Zeng YC. · · 2021 · cited 42× · PMID 33065386 · DOI 10.1016/j.tranon.2020.100889
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Ortega-Franco A, Ackermann C, Paz-Ares L, Califano R. · · 2021 · cited 29× · PMID 33450659 · DOI 10.1016/j.esmoop.2020.100003
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.
Cantini L, Pecci F, Merloni F, Lanese A, et al · · 2021 · cited 2× · PMID 36046087 · DOI 10.37349/etat.2021.00030
[Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer  in the Era of Immunotherapy].
Chen T, Yang Y, Han H, Liu D, et al · · 2025 · PMID 40506489 · DOI 10.3779/j.issn.1009-3419.2025.102.20

Verify or expand the search:

Other recruiting trials for Small Cell Lung Carcinoma

Currently open trials in the same condition.

NCT07015892 — Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial · Phase 3 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07006727 — Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · Phase 1 · recruiting
NCT06992609 — Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. · Phase 3 · recruiting

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03963414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 28 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03963414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing